Effect of Neurohormonal Blockade Drug Therapy on Outcomes and Left Ventricular Function and Structure After Left Ventricular Assist Device Implantation

Avishay Grupper, Yanjun M. Zhao, Pavol Sajgalik, Lyle D. Joyce, Soon J. Park, Naveen Luke Pereira, John M. Stulak, John C Jr. Burnett, Brooks Sayre Edwards, Richard C. Daly, Sudhir S. Kushwaha, John A. Schirger

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Neurohormonal blockade drug therapy (NHBDT) is the cornerstone therapy in heart failure (HF) management for promoting reverse cardiac remodeling and improving outcomes. It's utility in left ventricular assist device (LVAD) supported patients remains undefined. Sixty-four patients who received continuous flow LVAD at our institution were retrospectively reviewed and divided into 2 groups: no-NHBDT group (n = 33) received LVAD support only and NHBDT group (n = 31) received concurrent NHBDT based on the clinical judgment of the attending physicians. Cardiac remodeling (echocardiographic parameters and biomarkers) and clinical outcome (functional status, HF-related hospital readmissions, and mortality) data were collected. A statistically significant increase in ejection fraction, decrease in LV end-diastolic diameter index and LV mass index, and a sustained reduction in N-terminal pro B-type natriuretic peptide (NTproBNP) were observed in the NHBDT group at 6 months after LVAD implant (p

Original languageEnglish (US)
JournalAmerican Journal of Cardiology
DOIs
StateAccepted/In press - Jan 18 2016

Fingerprint

Heart-Assist Devices
Left Ventricular Function
Drug Therapy
Heart Failure
Patient Readmission
Brain Natriuretic Peptide
Hospital Mortality
Biomarkers
Physicians

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Effect of Neurohormonal Blockade Drug Therapy on Outcomes and Left Ventricular Function and Structure After Left Ventricular Assist Device Implantation. / Grupper, Avishay; Zhao, Yanjun M.; Sajgalik, Pavol; Joyce, Lyle D.; Park, Soon J.; Pereira, Naveen Luke; Stulak, John M.; Burnett, John C Jr.; Edwards, Brooks Sayre; Daly, Richard C.; Kushwaha, Sudhir S.; Schirger, John A.

In: American Journal of Cardiology, 18.01.2016.

Research output: Contribution to journalArticle

Grupper, Avishay ; Zhao, Yanjun M. ; Sajgalik, Pavol ; Joyce, Lyle D. ; Park, Soon J. ; Pereira, Naveen Luke ; Stulak, John M. ; Burnett, John C Jr. ; Edwards, Brooks Sayre ; Daly, Richard C. ; Kushwaha, Sudhir S. ; Schirger, John A. / Effect of Neurohormonal Blockade Drug Therapy on Outcomes and Left Ventricular Function and Structure After Left Ventricular Assist Device Implantation. In: American Journal of Cardiology. 2016.
@article{fbfbfe81c44b4cb5a649c35bb73064c3,
title = "Effect of Neurohormonal Blockade Drug Therapy on Outcomes and Left Ventricular Function and Structure After Left Ventricular Assist Device Implantation",
abstract = "Neurohormonal blockade drug therapy (NHBDT) is the cornerstone therapy in heart failure (HF) management for promoting reverse cardiac remodeling and improving outcomes. It's utility in left ventricular assist device (LVAD) supported patients remains undefined. Sixty-four patients who received continuous flow LVAD at our institution were retrospectively reviewed and divided into 2 groups: no-NHBDT group (n = 33) received LVAD support only and NHBDT group (n = 31) received concurrent NHBDT based on the clinical judgment of the attending physicians. Cardiac remodeling (echocardiographic parameters and biomarkers) and clinical outcome (functional status, HF-related hospital readmissions, and mortality) data were collected. A statistically significant increase in ejection fraction, decrease in LV end-diastolic diameter index and LV mass index, and a sustained reduction in N-terminal pro B-type natriuretic peptide (NTproBNP) were observed in the NHBDT group at 6 months after LVAD implant (p",
author = "Avishay Grupper and Zhao, {Yanjun M.} and Pavol Sajgalik and Joyce, {Lyle D.} and Park, {Soon J.} and Pereira, {Naveen Luke} and Stulak, {John M.} and Burnett, {John C Jr.} and Edwards, {Brooks Sayre} and Daly, {Richard C.} and Kushwaha, {Sudhir S.} and Schirger, {John A.}",
year = "2016",
month = "1",
day = "18",
doi = "10.1016/j.amjcard.2016.03.011",
language = "English (US)",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Effect of Neurohormonal Blockade Drug Therapy on Outcomes and Left Ventricular Function and Structure After Left Ventricular Assist Device Implantation

AU - Grupper, Avishay

AU - Zhao, Yanjun M.

AU - Sajgalik, Pavol

AU - Joyce, Lyle D.

AU - Park, Soon J.

AU - Pereira, Naveen Luke

AU - Stulak, John M.

AU - Burnett, John C Jr.

AU - Edwards, Brooks Sayre

AU - Daly, Richard C.

AU - Kushwaha, Sudhir S.

AU - Schirger, John A.

PY - 2016/1/18

Y1 - 2016/1/18

N2 - Neurohormonal blockade drug therapy (NHBDT) is the cornerstone therapy in heart failure (HF) management for promoting reverse cardiac remodeling and improving outcomes. It's utility in left ventricular assist device (LVAD) supported patients remains undefined. Sixty-four patients who received continuous flow LVAD at our institution were retrospectively reviewed and divided into 2 groups: no-NHBDT group (n = 33) received LVAD support only and NHBDT group (n = 31) received concurrent NHBDT based on the clinical judgment of the attending physicians. Cardiac remodeling (echocardiographic parameters and biomarkers) and clinical outcome (functional status, HF-related hospital readmissions, and mortality) data were collected. A statistically significant increase in ejection fraction, decrease in LV end-diastolic diameter index and LV mass index, and a sustained reduction in N-terminal pro B-type natriuretic peptide (NTproBNP) were observed in the NHBDT group at 6 months after LVAD implant (p

AB - Neurohormonal blockade drug therapy (NHBDT) is the cornerstone therapy in heart failure (HF) management for promoting reverse cardiac remodeling and improving outcomes. It's utility in left ventricular assist device (LVAD) supported patients remains undefined. Sixty-four patients who received continuous flow LVAD at our institution were retrospectively reviewed and divided into 2 groups: no-NHBDT group (n = 33) received LVAD support only and NHBDT group (n = 31) received concurrent NHBDT based on the clinical judgment of the attending physicians. Cardiac remodeling (echocardiographic parameters and biomarkers) and clinical outcome (functional status, HF-related hospital readmissions, and mortality) data were collected. A statistically significant increase in ejection fraction, decrease in LV end-diastolic diameter index and LV mass index, and a sustained reduction in N-terminal pro B-type natriuretic peptide (NTproBNP) were observed in the NHBDT group at 6 months after LVAD implant (p

UR - http://www.scopus.com/inward/record.url?scp=84962897541&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962897541&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2016.03.011

DO - 10.1016/j.amjcard.2016.03.011

M3 - Article

C2 - 27079215

AN - SCOPUS:84962897541

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

ER -